{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:37Z","timestamp":1792166317754,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000114"],"award-info":[{"award-number":["UL1TR000114"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA65493"],"award-info":[{"award-number":["P01 CA65493"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA111412"],"award-info":[{"award-number":["P01 CA111412"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA72669"],"award-info":[{"award-number":["R01 CA72669"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["ASH Scholar"],"award-info":[{"award-number":["ASH Scholar"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00262-017-2100-1","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T05:32:28Z","timestamp":1512624748000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhifaf","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Panoskaltsis-Mortari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Curtsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"issue":"2","key":"2100_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Duhrsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C (2017) Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant 52(2):216\u2013221. https:\/\/doi.org\/10.1038\/bmt.2016.213https:\/\/doi.org\/","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2100_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540\u2013549. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"2100_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","volume":"101","author":"NH Fowler","year":"2016","unstructured":"Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O\u2019Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K (2016) Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531\u2013540. https:\/\/doi.org\/10.3324\/haematol.2015.139493","journal-title":"Haematologica"},{"issue":"13","key":"2100_CR4","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA (2010) The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286\u20132294. https:\/\/doi.org\/10.1182\/blood-2010-02-271874","journal-title":"Blood"},{"issue":"11","key":"2100_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","volume":"59","author":"V Bachanova","year":"2010","unstructured":"Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59(11):1739\u20131744. https:\/\/doi.org\/10.1007\/s00262-010-0896-z","journal-title":"Cancer Immunol Immunother"},{"issue":"1Suppl","key":"2100_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bbmt.2011.10.033","volume":"18","author":"WJ Murphy","year":"2012","unstructured":"Murphy WJ, Parham P, Miller JS (2012) NK cells\u2013from bench to clinic. Biol Blood Marrow Transplant 18(1Suppl):2\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.033","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2100_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.smim.2014.02.002","volume":"26","author":"DA Knorr","year":"2014","unstructured":"Knorr DA, Bachanova V, Verneris MR, Miller JS (2014) Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 26(2):161\u2013172. https:\/\/doi.org\/10.1016\/j.smim.2014.02.002","journal-title":"Semin Immunol"},{"issue":"3","key":"2100_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tmrv.2005.02.007","volume":"19","author":"DH McKenna","year":"2005","unstructured":"McKenna DH, Kadidlo DM, Miller JS, Orchard PJ, Wagner JE, McCullough J (2005) The Minnesota molecular and cellular therapeutics facility: a state-of-the-art biotherapeutics engineering laboratory. Transfus Med Rev 19(3):217\u2013228","journal-title":"Transfus Med Rev"},{"issue":"27","key":"2100_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH et al (2014)\u00a0Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"2100_CR10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate\u2014a practical and powerful approach to multiple testing. J R Stat Soc B Met 57:289\u2013300","journal-title":"J R Stat Soc B Met"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501. https:\/\/doi.org\/10.1038\/ncomms10501","journal-title":"Nat Commun"},{"issue":"5","key":"2100_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001https:\/\/doi.org\/","journal-title":"Immunity"},{"issue":"13","key":"2100_CR13","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","volume":"119","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Lenvik TR, McCullar V, Felices M, O\u2019Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, Miller JS (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119(13):3064\u20133072. https:\/\/doi.org\/10.1182\/blood-2011-06-360321","journal-title":"Blood"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1038\/bcj.2015.1","volume":"5","author":"ZZ Yang","year":"2015","unstructured":"Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM (2015) PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J 5:e281. https:\/\/doi.org\/10.1038\/bcj.2015.1","journal-title":"Blood Cancer J"},{"issue":"9","key":"2100_CR15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3109\/10428194.2015.1011640","volume":"56","author":"ZZ Yang","year":"2015","unstructured":"Yang ZZ, Liang AB, Ansell SM (2015) T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. Leuk Lymphoma 56(9):2498\u20132504. https:\/\/doi.org\/10.3109\/10428194.2015.1011640","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2100_CR16","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","volume":"31","author":"S Kiaii","year":"2013","unstructured":"Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, Calaminici M, Neuberg DS, Gribben JG (2013) Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol 31(21):2654\u20132661. https:\/\/doi.org\/10.1200\/JCO.2012.44.2137","journal-title":"J Clin Oncol"},{"issue":"3","key":"2100_CR17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","volume":"186","author":"N Joller","year":"2011","unstructured":"Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK (2011) Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 186(3):1338\u20131342. https:\/\/doi.org\/10.4049\/jimmunol.1003081","journal-title":"J Immunol"},{"issue":"10","key":"2100_CR18","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/eji.201545480","volume":"45","author":"F Wang","year":"2015","unstructured":"Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, Yin B, Huang J, Mao L, Lu Y, Sun Z (2015) TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol 45(10):2886\u20132897. https:\/\/doi.org\/10.1002\/eji.201545480","journal-title":"Eur J Immunol"},{"issue":"12","key":"2100_CR19","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H (2016) T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8\u2009+\u2009T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22(12):3057\u20133066. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2626","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2100_CR20","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","volume":"76","author":"D Sarhan","year":"2016","unstructured":"Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS (2016) Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res 76(19):5696\u20135706. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0839","journal-title":"Cancer Res"},{"issue":"25","key":"2100_CR21","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123(25):3855\u20133866. https:\/\/doi.org\/10.1182\/blood-2013-10-532531","journal-title":"Blood"},{"issue":"Suppl2","key":"2100_CR22","doi-asserted-by":"publisher","first-page":"ii100","DOI":"10.1136\/ard.61.suppl_2.ii100","volume":"61","author":"FY Liew","year":"2002","unstructured":"Liew FY, McInnes IB (2002) Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 61(Suppl2):ii100\u2013i102","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2100_CR23","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V80.9.2221.2221","volume":"80","author":"JS Miller","year":"1992","unstructured":"Miller JS, Oelkers S, Verfaillie C, McGlave P (1992) Role of monocytes in the expansion of human activated natural killer cells. Blood 80(9):2221\u20132229","journal-title":"Blood"},{"issue":"9","key":"2100_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","volume":"14","author":"N Lapteva","year":"2012","unstructured":"Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14(9):1131\u20131143. https:\/\/doi.org\/10.3109\/14653249.2012.700767","journal-title":"Cytotherapy"},{"issue":"3","key":"2100_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","volume":"177","author":"N Shah","year":"2017","unstructured":"Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ (2017) Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457\u2013466. https:\/\/doi.org\/10.1111\/bjh.14570","journal-title":"Br J Haematol"},{"issue":"6","key":"2100_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955\u2013959. https:\/\/doi.org\/10.1200\/JCO.2009.24.4590https:\/\/doi.org\/","journal-title":"J Clin Oncol"},{"issue":"8","key":"2100_CR27","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","volume":"20","author":"JS Miller","year":"2014","unstructured":"Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20(8):1252\u20131257. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2100_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.bbmt.2006.01.009","volume":"12","author":"J Ayello","year":"2006","unstructured":"Ayello J, van de Ven C, Fortino W, Wade-Harris C, Satwani P, Baxi L, Simpson LL, Sanger W, Pickering D, Kurtzberg J, Cairo MS (2006) Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant 12(6):608\u2013622. https:\/\/doi.org\/10.1016\/j.bbmt.2006.01.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2100_CR29","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jcyt.2015.07.020","volume":"17","author":"S Vasu","year":"2015","unstructured":"Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs RW (2015) A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy 17(11):1582\u20131593. https:\/\/doi.org\/10.1016\/j.jcyt.2015.07.020","journal-title":"Cytotherapy"},{"issue":"1","key":"2100_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182(1):240\u2013249","journal-title":"J Immunol"},{"issue":"15","key":"2100_CR31","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","volume":"20","author":"Y Mao","year":"2014","unstructured":"Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A (2014) Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 20(15):4096\u20134106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0635","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2100_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2019","volume":"31","author":"T Tadmor","year":"2013","unstructured":"Tadmor T, Fell R, Polliack A, Attias D (2013) Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 31(3):65\u201371. https:\/\/doi.org\/10.1002\/hon.2019","journal-title":"Hematol Oncol"},{"issue":"8","key":"2100_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","volume":"128","author":"I Azzaoui","year":"2016","unstructured":"Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G, Godmer P, Bouabdallah K, Milpied N, Damaj G, Tarte K, Fest T, Roussel M (2016) T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood 128(8):1081\u20131092. https:\/\/doi.org\/10.1182\/blood-2015-08-662783","journal-title":"Blood"},{"issue":"12","key":"2100_CR34","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.4049\/jimmunol.1201018","volume":"189","author":"E Schlecker","year":"2012","unstructured":"Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A (2012) Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 189(12):5602\u20135611. https:\/\/doi.org\/10.4049\/jimmunol.1201018","journal-title":"J Immunol"},{"issue":"19","key":"2100_CR35","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33\u2009+\u2009targets. Blood 123(19):3016\u20133026. https:\/\/doi.org\/10.1182\/blood-2013-10-533398","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2100-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T10:19:45Z","timestamp":1719656385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2100-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2100-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]},"assertion":[{"value":"1 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Eisai Inc has provided denileukin diftitox for this trial and supported the correlative assays. Veronika Bachanova receives funding from GT Biopharma Inc, Novartis and serves on advisory board for Seattle-Genetics. Other authors have no relevant conflicts of interest to report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}